Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Annexin 1 exerts anti-nociceptive effects after peripheral inflammatory pain through formyl-peptide-receptor-like 1 in rat dorsal root ganglion.

Authors: Pei, L  Zhang, J  Zhao, F  Su, T  Wei, H  Tian, J  Li, M  Shi, J 
Citation: Pei L, etal., Br J Anaesth. 2011 Dec;107(6):948-58. doi: 10.1093/bja/aer299. Epub 2011 Oct 11.
Pubmed: (View Article at PubMed) PMID:21990306
DOI: Full-text: DOI:10.1093/bja/aer299

BACKGROUND: Annexin 1 (ANXA1) has analgesic effects in inflammatory pain. We aimed to investigate the anti-nociceptive role of ANXA1, at the dorsal root ganglion (DRG) level, through an interaction with formyl-peptide-receptor-like 1 (FPR2/ALX). METHODS: Inflammatory pain was evoked by injecting complete Freund's adjuvant (CFA, 50 mul) into the hindpaw of male Sprague-Dawley rats. The distribution of ANXA1 and FPR2/ALX in L4/5 DRGs was evaluated by immunofluorescence. The expression of ANXA1 was measured by western blot. The involvement of FPR2/ALX in the anti-nociception of ANXA1 was investigated by thermal (irradiant heat) and mechanical (von Frey filament) pain tests with intrathecal (i.t.) ANXA1-derived peptide (Anxa1(2-26)), FPR2/ALX agonist 5(S)-6(R)-7-trihydroxyheptanoic-acid-methyl-ester (BML-111), and antagonist N-t-Boc-Phe-Leu-Phe-Leu-Phe (Boc1). RESULTS: ANXA1 and FPR2/ALX localized in the satellite glial cells and neurones in L4/5 DRGs. CFA treatment (n=20) increased ANXA1 expression in L4/5 DRGs within 7 days (P<0.01). I.T. Anxa1(2-26) (20 and 100 microg microl(-1)) and BML-111 (10 and 100 nmol) reduced CFA-induced thermal and mechanical nociception within 48 h (n=40) (P<0.05). However, i.t. Boc1 10 microg intensified inflammatory pain (P<0.05) and reversed the anti-nociceptive effect of Anxa1(2-26) (n=25) (P<0.05). Moreover, ANXA1 expression increased in L4/5 DRGs after i.t. Anxa1(2-26) (20 microg microl(-1)) (P<0.05) and BML-111 (10 nmol) (P<0.01) but decreased after i.t. Boc1 (10 and 100 microg) alone (P<0.01) or Boc1 (10 microg) co-injection with Anxa1(2-26) (20 microg microl(-1)) (P<0.05). CONCLUSIONS: Endogenous ANXA1 expression at the DRG level is involved in CFA-induced inflammatory pain, and i.t. ANXA1 20 microg microl(-1) produces its anti-nociceptive effect through FPR2/ALX.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 7421656
Created: 2013-11-26
Species: All species
Last Modified: 2013-11-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.